Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS) are a group of blood disorders caused by the ineffective production of blood cells in the bone marrow, leading to symptoms like fatigue, weakness, and increased risk of infections.
Myelodysplastic Syndrome: Oral Azacitidine Study
We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a diagnosis of myelodysplastic syndrome (MDS)?
- Do you have at least one type of low blood cell count, like anemia or low platelets?
- Is your ECOG performance status 0, 1, or 2 (meaning you are fully active or have some limitations)?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Ordensklinikum Linz GmbH
Haematology & Oncology
Linz, Austria
Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH
3rd Medical Department
Salzburg, Austria
Hanusch Krankenhaus Der Wiener Gebietskrankenkasse
Haematology & Oncology
Vienna, Austria
Sponsor: Celgene Corp.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.